Osaka University to begin world’s first iPS cell-based therapy for the heart
Prof. Yoshiki Sawa, Department of Cardiology, has been using iPS cells to develop cell therapies for the heart. The project has been conducted with funding from the Japan Agency for Medical Research and Development.
Based on the success in animal experiments, last year, the Sawa group submitted a clinical research plan to used cells manufactured from iPS cells to treat patients with heart disease. Due to the nature of the therapy, the plan was categorized as class I (high risk) regenerative medicine. This past May 16th, the plan was conditionally approved by the Ministry of Health, Labour and Welfare.
【Clinical Research Summary】
The safety and feasibility of iPSC-derived cardiac cell sheet transplantation on patients with severe ischemic cardiomyopathy will be examined.
・Number of cases：3
・Number of transplanted cells：1×108 per patient
・Observation period：1 year
・Main evaluation item: safety and feasibility
・Secondary evaluation item: Cardiac function as assessed clinically
